rfk glp-1 Jr. Could Shake up the Weight Loss Industry in the Age of Ozempic FDA to weigh looser rules

Description

While existing GLP-1 medications have shown greater weight loss than Lillys oral medication, this option targets both weight loss and type 2 diabetes in patients.

Aims/hypothesis Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) in individuals taking liraglutide and semaglutide

The battle over America's booming weight-loss drug market has a significant update, with a move thats likely to cause a shift across the healthcare and corporate benefits landscape: Cigna, one of Americas biggest insurers, is dropping coverage for GLP-1 obesity drugs, even for its own staff